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In 1990 Charles Hepler and Linda Strand published a sentinel
paper and coined the term ‘Pharmaceutical Care’. This was
defined as ‘that component of pharmacy practice which entails
the direct interaction of the pharmacist with the patient for the
purpose of caring for that patient’s drug-related needs’.1
In 1996 the Regional Pharmaceutical Officers’ Statement
of Principles and Standards of Good Practice for Hospital
Pharmacy in the UK stated that ‘All patients will receive the
medicines to meet their agreed therapeutic objectives throughout
the course of their treatment. This requires that the care plan
for each patient identifies the correct choice of medication and
is supported by systems for the provision of medicines…’ and
‘Patients will be assessed to determine their pharmaceutical
care needs and to minimise risk factors likely to prejudice the
outcome of their care’.
In 2003 The Society of Hospital Pharmacists of Australia
(SHPA) Standards of Practice for Clinical Pharmacy, were
published utilising these core concepts and applied them to
Australian health care.2
In April 2004, all Australian Health Ministers agreed, as
one of seven key patient safety deliverables, that public hospitals
should: ‘provide a pharmaceutical review of prescribing,
dispensing, administration and documentation of
medications for all inpatients by December 2006’.3 This bold
and encompassing statement places the hospital pharmacist
central to the delivery of quality use of medicines. It also defines
that services should be delivered to a minimum standard
promoting the standards espoused by hospital pharmacists.
Well intentioned agreements require subsequent processes
that result in tangible changes in patient care. These processes
are often torturous and difficult to implement. The lack of any
definition of what constitutes pharmaceutical review, the lack
of appropriately trained staff and the pressure to deliver on
many administrative tasks have combined to inhibit change in
Australian pharmacy practice. Many considered that this was
just ‘a bridge too far’ and in the end pharmacists would continue
to try to provide their very well intentioned but sometimes
inefficient clinical services.
However, in Queensland Health, the Safe Medication
Practice Unit (SMPU) was provided with the resources to
establish a reproducible process to assist the pharmacy workforce
to achieve this ministerial commitment. Firstly, a working definition
for pharmaceutical review was adapted from that developed by
the Australian Council for Safety and Quality in Health Care and
Pharmaceutical Review—A View from Academia
A key issue in delivery of health services is the training required
to deliver, as well as to ‘quality assure’ those services.
Furthermore, there are clear differences between the types of
education and training required to achieve different educational
objectives, for example, qualification for practice, demonstration
of competency, or credentialing to provide a specific (higher
level or specialist) service.
Among many health professionals, training encompasses
a mixed model of on-campus and experiential and clinical training
in healthcare settings and related organisations. This training
may be along a continuum from undergraduate to continuing
education in postgraduate programs.
Universities have a set of ‘graduate attributes’ that are
general to the tertiary community, as well as profession-specific
requirements of our graduates. The universities provide
education and training to ensure our pharmacy graduates are
prepared to meet entry level competencies (after they have
successfully completed postgraduate, preregistration
experience, and have met the state-based requirements for
registration as a pharmacist). Many universities provide
postgraduate pharmacy courses—these courses may have a
range of different objectives—in research training as well as
updating knowledge and ‘upskilling’ in a range of specialist
therapeutic areas and services.
Implementation of pharmaceutical review will require a
workforce that can move through a structured career path which
includes experience, practice development and relevant formal
training. To provide support for training to provide higher level
practice, as in the UK model, then any postgraduate training
provided by the universities would of course need to be directly
relevant to and ‘twinned’ with the practice environment.
Partnerships between the universities and the health
services are needed to develop and deliver such courses. The
aims, content and delivery of these courses will have to be
developed in these partnerships. There may be the possibility
of consortia among universities to accredit clinical training, or
to combine the delivery of courses from both the health services
and the universities.
Given workload pressures, we will have to find new ways
to facilitate access by current practitioners to formal training
programs. Different approaches might include more flexible
course delivery, online resources, release time, secondments,
clinical residencies, as well as other innovative ways of providing
and undertaking further training in the crowded workplace. This
need for ongoing training will also be taking place in the
environment where there are ongoing and increasing pressures
to accommodate the training of undergraduate students. Our
hospitals are already ‘crowded’ in terms of students on
placements and also in terms of workload pressures.
However, these are predictable challenges, and are not
insurmountable—as long as there is timely, collaborative work
undertaken by the university and hospital sectors. The benefits
of a well-trained, ‘pharmaceutical review-ready’ set of
practitioners will be a very valuable investment in the future of
hospital pharmacy practice.
Professor Jo-anne Brien, BPharm, BSc(Pharm),
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Editor-in-Chief
Journal of Pharmacy Practice and Research
Suite 3, 65 Oxford Street
Collingwood Vic. 3066
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A number of individuals have offered editorial comments about
pharmaceutical review, from a range of perspectives. It seems
that pharmaceutical review, around the country might provide
the impetus to achieve many advances in the organisation of
pharmacy services. Many of these services may have been
identified previously, and some are currently in practice.
Pharmaceutical review may provide opportunities to formalise
the ‘language’ around statements of competencies for practice,
to achieve a national approach to frameworks for general and
advanced level practice, career paths and definitions of
pharmacy activities and services in the context of health service
delivery. This may be a long awaited opportunity to bring
pharmacy into the ‘mainstream’ of clinical services delivery in
hospitals, and more broadly.
If pharmaceutical review can achieve this—we must seize
the opportunity. The journal provides a forum for discussion
about pharmaceutical review, and other issues. We await your
letters and manuscripts!
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endorsed by Queensland Health in 2005: ‘A minimum standard
of systematic appraisal of all aspects of patients’ medication
management within an institution conducted (or supervised) by a
qualified and suitably trained health professional (ideally a
pharmacist) acting as part of a multidisciplinary team. It includes
objective review of medication prescribing, dispensing,
distribution, administration, monitoring of outcomes and
documentation of medication related information in order to
optimise the quality use of medicines (QUM)’.
The key activities encompassed within pharmaceutical
review have been agreed by senior clinical pharmacy, medical
and nursing staff and align closely with the Australian
Pharmaceutical Advisory Council (APAC) Guiding Principles to
Achieve Continuity in Medication Management, to which
Queensland Health, like many other states has made a
commitment, as a component of the pharmaceutical reform
agenda. Similarly, they are aligned with the SHPA Standards of
Practice for Clinical Pharmacy, and the combined Pharmacy
Professional Competency standards of practice.2 In addition there
are, albeit relatively vague, capability frameworks for pharmacy
services which describe the core activities that should occur in
different size sites. With many definitions, standards and guidelines,
there is a risk that they remain on shelves or desk tops and never
result in any meaningful improvement in patient outcomes.
An essential prerequisite to change is to understand the
current standard of pharmaceutical review, how frequently
reviews are performed and to identify the gaps and then agree
efficient processes by which effective services can be developed.
The General Level Framework (GLF), produced by the
Competency Development and Evaluation Group (CODEG) in
South East England <www.codeg.org> and implemented by many
acute hospitals in the NHS in England and further afield, was a
response to the need to provide a consistent standard of clinical
pharmacy practice at an individual and service level.4 The GLF
consists of three competency clusters: delivery of patient care,
problem solving and personal attributes. Each competency is
described by a series of behavioural indicators. The delivery of
patient care cluster, focuses on clinical performance and is aligned
to the pharmaceutical care or drug use process and reflects upon
core service areas such as medication history taking and
reconciliation, drug problem prevention, identification and
resolution. The personal and problem solving clusters describe
the generic skills of individuals such as core knowledge required,
ability to communicate effectively and work as part of a team
whilst being effective and efficient.5
The GLF allows self and peer objective evaluation of
performance, enables feedback to individuals and managers on
the level and standard of practice and allows targeted objectives
to be set for individuals and services, using objective outcomes.
Evidence from a controlled study demonstrates that when utilised
regularly among those delivering a level of service consistent with
post-registration practice (termed ‘general level pharmacists’), a
significant and sustained improvement in patient care competencies
was demonstrated when compared to control sites.6
The process undertaken in Queensland has been to agree
to definitions, develop and agree to a framework that assists
prioritisation of clinical tasks essential to good patient care based
on high-risk medicines and high-risk patient groups. This risk-
based patient prioritisation was then mapped to activities as
outlined in the SHPA core standards and agreed at workshops
by senior clinical pharmacists. The GLF has now been formally
adopted, in collaboration with CODEG, to deliver the
recommendations outlined in the APAC principles and SHPA
Standards of Practice for Clinical Pharmacy. The amended GLF
was endorsed by Queensland Health Directors of Pharmacy in
October 2006. It describes the pharmaceutical review activities
expected of a competent general level pharmacist after undertaking
minimum experiential training. In addition, this practical tool to
evaluate pharmacists, provide feedback and direct clinical
practitioners’ behaviours will go a long way to meet the objectives
of the new Safety and Quality Commission to establish
appropriate credentialing processes for all clinicians. Perhaps, in
this area pharmacy may now be a leader rather than a follower.
The process has been extremely well received by
practitioners with over half of Queensland Health sites now utilising
this process with all sites involved by the end of February 2007.
The majority of clinicians have previously never received any
objective evaluation and feedback on their clinical practice. Most
importantly, virtually all have seen it as a positive and constructive
process and a number of sites are undergoing second rounds of
evaluation. Many of the gaps identified are system issues, such
as the need for a standardised approach to medication history
taking, documentation, confirmation and reconciliation, both
within and between institutions. This in itself has resulted in a
statewide approach to a medication action plan, one of the core
components of the process described both in the APAC guidelines
and SHPA Standards of Practice for Clinical Pharmacy.
Re-evaluations of practitioners are now occurring two to
three times a year, depending on resources. Large sites with
established training and mentor positions have quickly become
independent. Small sites have been assisted with training and
support by SMPU to undertake both the assessments and
feedback process and establish local clinical training. In addition,
gaps identified in the process of patient consultation, problem
prioritisation and effective resolution with medical, nursing staff
and patients has resulted in a skills-based training program being
developed, adapted from the already established preregistration
induction course. This will be run repeatedly each year by SMPU
to assist with practitioner development and training.
Clearly, appropriate numbers as well as competencies of
staff are required to deliver pharmaceutical review and a gap
analysis has been undertaken against the suggested pharmacist-
to-patient ratios and used to direct a parallel and essential
component of work which is under way to identify staffing needs
and link with a service capability program to clearly identify
what pharmacy resources are required by Queensland Health
to deliver the key essential pharmacy services.2 The initial gap
analysis has already resulted in a significant increase in the
number of preregistration pharmacist positions which has
increased from less than 20, three years ago to almost 60 across
the state by January 2007.
To ensure a sustainable system and maintain enthusiasm
for this process, a revised career framework is being developed
as part of an ongoing interest-based bargaining process, which
hopes to establish a totally revised career framework, service
delivery model and training and development program with a
revised recruitment and retention strategy by 2008.
A pharmaceutical review deliverable has been a catalyst for
a practitioner and service development process, in Queensland
Health facilities. National endorsement of a GLF for delivery of
pharmaceutical review activities could be a constructive approach
with hospital pharmacy leading the way in the new era of health
services’ standards ensuring that appropriate practitioners are
being developed or are practising at the appropriate standard to
deliver acceptable patient care. Let hospital pharmacists not wait
for the policy makers to tell them how to implement their policies.
Let them demonstrate that they are, together with multidisciplinary
colleagues, both innovators and implementers of essential
components of the appropriate standard of medication
management for Australian patients.
Ian Coombes
Team Leader, Pharmaceutical Review
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Pharmaceutical Review—A Lost Opportunity?
In 2004 the Australian Health Ministers released a joint
communiqué which called for a process of pharmaceutical
review of medication prescribing, dispensing, administration and
documenting processes for the use of medicines to be available
in every hospital by the end of 2006. Was this a mandate for
the pharmacy profession to come forward and take responsibility
and be accountable for the safe, effective and judicious use of
medicines in our hospitals?
I feel that the concept of pharmaceutical review was borne
out of the safety in healthcare agenda and was an opportunity
to show that pharmacists can make a real and significant
contribution to reducing harm and improving outcomes
associated with the use of medicines. Pharmaceutical review
essentially brings together the principles of the Quality Use of
Medicines, the Guiding Principles for Medicines Management
in the Community and The Society of Hospital Pharmacists of
Australia’s Standards of Practice for Clinical Pharmacy, but
needs to function not only at the individual patient level but also
at the hospital and health systems level. It thus needs to be a
multidisciplinary approach with the need to break down the
silos between the different health professionals involved in
patient care. Pharmacists are ideally placed for this task, as we
have the key knowledge and skills in this area, to take a
leadership role in defining and implementing what
pharmaceutical review might look like in practice.
The time has come for us to stop abdicating responsibility
to other healthcare staff and be present to carry out medication
histories, to identify medication-related problems, to formulate
medication action plans and to monitor outcomes for all patients.
This means being available outside of normal office hours, in all
areas of the hospital where medicines are used and in hospitals
outside of the urban and metropolitan areas. We need to develop
relationships with rural hospitals and with health centres in remote
communities and inspire the new generation of pharmacists to
have a broader view of hospital pharmacy practice. This, coupled
with the use of technologies such as voice and video over Internet,
electronic medicine management systems and robotics for remote
dispensing, will allow us to create new types of therapeutic
relationships with people as they move through the continuum of
care boundaries regardless of where they live.
The end of 2006 is upon us, we need national co-ordination
and leadership from within the profession to ensure that
pharmaceutical review is not a lost opportunity.
Pharmacy Services to Improve Continuity of
Care—Is It Time for a National Approach?
In South Australia, pharmacy service models to improve quality
use of medicines for patients along the continuum of care between
hospital and community have been developed over the last ten
years. These models have more recently been coined Medication
Management Services. All other States and Territories have
likewise progressed these services to address the implementation
of APAC guidelines.1 These evolving pharmacist roles have been
referred to with various titles including Community Liaison
Services, Medication Liaison Services and Hospital Outreach
Medication Reviews. I would like to suggest that it is time we
have a national consensus approach to determining a common
title for these services and development of standards of practice,
competencies and an evaluation framework.
In my experience, to achieve optimal patient outcomes along
the continuum there are essential service requirements. It is
imperative that the title defining these pharmacist activities within
the current Australian healthcare system adequately reflects all
of these requirements.2,3 Foremost, this involves effective
communication transfer with accurate, comprehensive and timely
transfer of patient-specific medication information that relies on
bi-directional not uni-directional flow of information across the
interface. Integration and coordination within the healthcare team
is also paramount, as is flexibility to span across all healthcare
settings including domiciliary, residential aged care and transition
care. Flexibility relates to not only to setting but also the ability to
link with existing services in the community—either facilitating
the ongoing community service or providing the service where
there is a gap in patient care. Hence, I do not believe that words
such as ‘community’ (inferring that these activities are setting
based) or ‘liaison’ (inferring that facilitation is the only requirement)
are necessarily the best descriptors of these pharmacist roles.
Are Hospital Outreach Medication Reviews perceived by
Australian pharmacists to be the same as Medication
Management Services and are Medication Management Services
perceived to be the same as Clinical Pharmacy Services? Inherent
in the answers to these questions is a paradigm shift from hospital
pharmacists relinquishing responsibility for patient care once the
patient is transferred to providing a clinical pharmacy service
that claims responsibility for ongoing care as the patient moves
out of the hospital front doors into the community. Maybe we
have all reached this paradigm shift, maybe not, however it is
definitely time to have these discussions at a national level, if
nothing else, so that when referring to these evolving pharmacist
roles everyone is on the same playing field.
Lisa Spurling, BPharm, GradDipComPracPharm,
MSc(Pharm)
Senior Specialist Clinical Pharmacy and Drug Information
Services
Flinders Medical Centre
Bedford Park SA 5042
E-mail: lisa.spurling@fmc.sa.gov.au
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